Moreover, cell cycle protein-dependent kinase 7 (CDK7) inhibitor THZ1 could downregulate PD-L1 expression by inhibiting MYC activation, and when combined with the PD-L1 inhibitor Atezolizumab improves the outcome of NSCLC [28]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.